The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia
| العنوان: | The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia |
|---|---|
| المؤلفون: | J. Nomdedeu, Ruth M. Risueño, Marta Pratcorona, Carmen Pedro, Mar Tormo, M.P. Queipo de Llano, Meritxell Nomdedeu, Montserrat Arnan, Lourdes Escoda, Jordi Esteve, Alfons Navarro, Josep Martí, J. Bargay, S Brunet, Montserrat Hoyos, David Gallardo, Marina Díaz-Beyá, Olga Salamero, Anna Cordeiro, Josep-Maria Ribera, Antonia Sampol, Inmaculada Heras, Joan J. Castellano, Josep M. Sierra, Mariano Monzo |
| المساهمون: | [Díaz-Beyá,M, Pratcorona,M, Nomdedeu,M, Esteve,J] Hematology Department, IDIBAPS, Hospital Clinic Villarroel, Barcelona, Spain. [Díaz-Beyá,M, Brunet,S, Nomdedéu,J, Ribera,JM, Risueño,RM, Sierra,J, Esteve,J] Josep Carreras Leukaemia Research Institute, Barcelona, Spain. [Brunet,S, Hoyos,M, Sierra,J] Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Spain. [Cordeiro,A, Castellano,JJ, Monzó,M, Navarro,A] Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Spain. [Tormo,M] Hematology Department, Hospital Clínico, Valencia, Spain. [Escoda,L] Hematology Department, Hospital Joan XXIII, Tarragona, Spain. [Ribera,JM] Hematology Department, Institut Català D'Oncologia (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain. [Arnán,M] ICO, Hematology Department, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain. [Heras,I] Hematology Department, Hospital Morales Meseguer, Murcia, Spain. [Gallardo,D] Hematology Department, ICO Josep Trueta, Girona, Spain. [Bargay,J, Sampol,A] Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca, Spain. [Queipo de Llano,MP] Hematology Department, Hospital Virgen de la Victoria, Málaga, Spain. [Salamero,O] Hematology Department, Hospital Vall D'Hebron, Barcelona, Spain. [Martí,JM] Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain. [Pedro,C] Hematology Department, Hospital del Mar, Barcelona, Spain. [Esteve,J] University of Barcelona, Spain., Marina Díaz-Beyá is supported by ISCIII (Río Hortega CM13/00205). This research was in part supported by Fundación Española de Hematología y Hemoterapia (beca de investigación MDB). This research is also supported by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III PI13/00999 (PI: JE), RETICS RD12/0036/0010 (JE, MDB) and SDCSD from School of Medicine, University of Barcelona, AECC-Catalunya 2013 (AN) (sponsored by Mat Holding), and grants AGAUR 2014SGR-1281, ISCIII RD12/0036/0071 and PI014/00450 (JS). Anna Cordeiro is an APIF fellow of the University of Barcelona., Universitat de Barcelona |
| المصدر: | Blood Cancer Journal r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Recercat. Dipósit de la Recerca de Catalunya Dipòsit Digital de la UB Universidad de Barcelona Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona |
| بيانات النشر: | NATURE PUBLISHING GROUP, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Male, Oncology, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings], Micro RNAs, proteínas de neoplasias, Myeloid, modelos de riesgos proporcionales, humanos, Mitoxantrona, adolescente, Kaplan-Meier Estimate, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Cytarabine [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Leucemia mieloide aguda, Risk Factors, Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Idarrubicina, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthalenes::Tetrahydronaphthalenes::Podophyllotoxin::Etoposide [Medical Subject Headings], Cumulative incidence, supervivencia sin enfermedad, mediana edad, BAALC, leucemia, anciano, MicroARNs, Leukemia, análisis citogenético, Hematology, Pronóstico, Myeloid leukemia, MicroRNA Expression Profile, adulto, Middle Aged, Prognosis, Neoplasm Proteins, Humanos, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Chromosomes::Karyotype [Medical Subject Headings], adulto joven, Malalts de càncer, pronóstico, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Cytogenetic Analysis, Female, Original Article, Incidencia, estimación de Kaplan-Meier, Adult, medicine.medical_specialty, Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [Medical Subject Headings], Adolescent, Pronòstic mèdic, Leucèmia mieloide, Anciano, Recurrencia, Citogenética, Biology, Etopósido, Disease-Free Survival, Young Adult, Cariotipo, Internal medicine, Análisis multivariante, Biomarkers, Tumor, medicine, factores de riesgo, Humans, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Anthracenes::Anthraquinones::Mitoxantrone [Medical Subject Headings], Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Leucèmia mieloide aguda -- Aspectes genètics, Aged, Proportional Hazards Models, Análisis citogenético, Proportional hazards model, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Genetics::Cytogenetics [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytogenetic Analysis [Medical Subject Headings], Cancer patients, microARN, medicine.disease, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings], Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [Medical Subject Headings], transcriptoma, MicroRNAs, Citarabina, Immunology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Transcriptome, Expresión génica |
| الوصف: | Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. Marina Diaz-Beya is supported by ISCIII (Rio Hortega CM13/00205). This research was in part supported by Fundacion Espanola de Hematologia y Hemoterapia (beca de investigacion MDB). This research is also supported by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III PI13/00999 (PI: JE), RETICS RD12/0036/0010 (JE; MDB) and SDCSD from School of Medicine, University of Barcelona, AECC-Catalunya 2013 (AN) (sponsored by Mat Holding), and grants AGAUR 2014SGR-1281, ISCIII RD12/0036/0071 and PI014/00450 (JS). Anna Cordeiro is an APIF fellow of the University of Barcelona. |
| وصف الملف: | application/pdf |
| تدمد: | 2044-5385 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2b4c6c2c6e60b3178849b5975957796 https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8303 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c2b4c6c2c6e60b3178849b5975957796 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20445385 |
|---|